The present invention relates to a compounds of formula Iwherein A, Ar, R, R2, R3, R4, p, and o are as defined in the specification and claims or to a pharmaceutically active salt thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinsons disease, schizophrenia, bipolar disorders, anxiety and attention deficit hyperactivity disorder (ADHD).
